Skip to main content

Investigating patients’ preferences for new anti-diabetic drugs to inform public health insurance coverage decisions: a discrete choice experiment in China



Diabetes is a major public health concern with a considerable impact on healthcare expenditures. Deciding on health insurance coverage for new drugs that meet patient needs is a challenge facing policymakers. Our study aimed to assess patients’ preferences for public health insurance coverage of new anti-diabetic drugs in China.


We identified six attributes of new anti-diabetic drugs and used the Bayesian-efficient design to generate choice sets for a discrete choice experiment (DCE). The DCE was conducted in consecutive samples of type 2 diabetes patients in Jiangsu Province. The mixed logit regression model was applied to estimate patient-reported preferences for each attribute. The interaction model was used to investigate preference heterogeneity.


Data from 639 patients were available for analysis. On average, the most valued attribute was the improvement in health-related quality of life (HRQoL) (β = 1.383, p < 0.001), followed by positive effects on extending life years (β = 0.787, p < 0.001), and well-controlled glycated haemoglobin (β = 0.724, p < 0.001). The out-of-pocket cost was a negative predictor of their preferences (β = -0.138, p < 0.001). Elderly patients showed stronger preferences for drugs with a lower incidence of serious side effects (p < 0.01) and less out-of-pocket costs (p < 0.01). Patients with diabetes complications favored more in the length of extended life (p < 0.01), improvement in HRQoL (p < 0.05), and less out-of-pocket costs (p < 0.001).


The new anti-diabetic drugs with significant clinical effectiveness and long-term health benefits should become the priority for public health insurance. The findings also highlight the value of accounting for preference heterogeneity in insurance policy-making.

Peer Review reports


Diabetes is a group of metabolic disorders characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both [1]. Diabetes imposes a heavy burden on public health. Global diabetes prevalence in 2019 was estimated to be 9.3% (463 million people), rising to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [2]. Over time, diabetes can lead to multiple serious long-term complications such as kidney failure, blindness, heart attacks, stroke, and lower limb amputation [3]. Furthermore, diabetes and its complications impose significant economic impacts on individuals and their families, health systems, and national economies [4]. Most patients need to take anti-diabetic drugs for their whole lives to stabilize and control their blood glucose levels. In recent years, newer anti-diabetes drugs have been developed, not only helping reduce blood glucose levels but also helping slow or prevent the progression of the disease [5].

In China, there are currently over 114 million people with diabetes [6]. The estimated diabetes-related health expenditures in China reached USD 109.0 billion in 2019, posing a massive challenge to the country’s health insurance system [4]. To alleviate the financial burden of patients and boost the utilization of necessary healthcare services, China achieved universal health insurance coverage in 2011 with 95% of its population covered by public health insurance programs [7]. However, gaps remain in the quality of care, control of chronic diseases, control of health expenditures, and public satisfaction [8]. To enhance equity and improve efficiency, patient values need to be considered in the determination of health insurance coverage scope [9].

Nowadays, one of the guiding principles of China’s public health insurance programs is to make Chinese have a greater sense of fulfillment, happiness, and security [10]. Public health insurance programs in China adhere to the people-centered approach and try to meet the reasonable medication needs of the insured [11]. Patient preference is also an essential element in the benefit-risk assessment of new drugs in China [12]. Taking into account the patient voice in health insurance decision-making can result in reimbursement of health technologies that are accepted by patients [13, 14]. Patients would be satisfied with health insurance schemes if the reimbursed health technologies meet their preferences [15, 16]. Nevertheless, direct patient involvement was thought to be subjective, potentially biased, and lacking representativeness [17, 18]. To explore the patient voice in a robust manner, it is necessary to quantify patients’ preferences before they can be adequately considered [18]. As shown in a systematic review, patients’ preferences could be quantitatively generated to inform health insurance decisions [19].

A key component of the evidence base that can guide decision-making on public health insurance coverage is patient values. Recognition of patient values has led to a shift in health technology assessment (HTA) from only looking at clinical outcomes to taking into account the patients’ perceptions of how these outcomes are related to their lives [20, 21]. Incorporating patients’ views into healthcare decisions improves patient satisfaction while fostering healthcare services more strongly aligned with their preferences and expectations [22, 23]. Previous studies in foreign countries showed successful experiences of integrating patient and public preferences into health insurance coverage decision-making [24,25,26,27]. However, the assumption of homogeneity in preferences across individuals can lead to misleading policy conclusions [28]. Accounting for preference heterogeneity is important in order to obtain unbiased estimates.

One well-established quantitative technique to elicit stated preferences is the discrete choice experiment (DCE), which allows participants to choose the alternative that maximizes their utility. By observing trade-offs as the participants accomplish a series of choice tasks, DCEs were able to predict choices-mimicking real-world decisions [29, 30]. Previous DCEs on diabetes patients’ preferences mainly focused on therapeutic interventions in clinical settings and several attributes of anti-diabetic drugs were identified, such as the chance of reaching the target glycated haemoglobin (HbA1c) level [31, 32], risk of hypoglycemia [31], risk of gastrointestinal problems [32], mode of drug administration [33], out-of-pocket costs, and life expectancy [34]. Health-related quality of life (HRQoL) is an important health outcome, representing one of the major goals of health interventions. To the best of our knowledge, HRQoL was seldom used as an attribute to investigate patients’ preferences for anti-diabetic drugs.

Health insurance decision-making is a complicated process. Few studies to date have examined whether diabetic patients’ preferences for insurance coverage varied according to their demographic features. Diabetes can lead to the development of chronic complications, which increase the disease severity [35, 36]. Despite having the highest prevalence of diabetes of any age group, older patients and/or those with complications have often been excluded from clinical trials [37]. Therefore, decision-makers did not have sufficient evidence regarding patient values of new treatment options for the population. In addition, diabetes poses economic burdens on patients and their families. Previous studies in China showed that low-income patients were more likely to experience catastrophic health expenditure as a result of diabetes care [38]. However, the impact of income on patients’ preferences for insurance coverage of new anti-diabetic drugs was rarely validated.

The assessment of patients’ preferences is necessary to understand the demand for insurance reimbursement. To expand the existing knowledge in this area, our DCE aimed to determine the relative importance of attributes of new anti-diabetic drugs for health insurance coverage from patients’ perspectives. We hypothesized that attributes relevant to health benefits might have the highest ranking, and patients’ preferences differed by age, level of income, and whether they had diabetes complications.


Identification of technology attributes and levels

We took a three-step approach in the preliminary stage of DCE, which aimed to define the attributes and levels of new anti-diabetic drugs. First, a literature review was conducted to identify attributes that were used in previous DCEs on diabetes therapy, management, and policy-making. Data extraction form of attributes and levels was developed according to the EVIDEM framework for integration of evidence and value in decision-making [39, 40]. A flow diagram of the identification of included studies is shown in Appendix 1. Our review found that the attributes mainly involved effectiveness, safety/tolerability, convenience, economic consequence, and patient-reported outcomes (Appendix 2).

Second, since the universe of attributes was vast, focus group discussions with physicians, health insurance decision-makers, and healthcare experts were carried out to determine the attributes. To better define the levels of attributes, we also searched the widely used HTA database established by the National Institute for Health and Care Excellence and the Canadian Agency for Drugs and Technologies in Health, then identified HTA reports for the new drugs treating diabetes. We found 47 reports which had been published before 19th August 2020 and analyzed the attributes and levels of new anti-diabetic drugs.

Finally, a pilot survey with 116 type 2 diabetes patients was conducted to provide feedback on the intelligibility and acceptability of the questionnaire. Responses from the patients led to a more explicit and apprehensible statement of the survey questions. Attributes and levels of new drugs used in our research are listed in Table 1. In this study, we defined new anti-diabetic drugs as the drugs which had been marketed in China for the treatment of diabetes but were not covered by the public health insurance programs. The explanations of attributes and levels are shown in Appendix 3.

Table 1 Attributes and levels of new anti-diabetic drugs in the DCE

Experimental design and development of the questionnaire

We used Ngene1.2 software (Choice-Metrics, Sydney, Australia) to implement the Bayesian D-efficiency experimental design. The blocking technique was conducted to promote response efficiency by reducing the potential cognitive burden on respondents [41]. Our experimental design comprised 48 pairs of scenarios split into six blocks. The final scenarios with orthogonality, attribute level balance, partial attributes or levels overlap and utility balance was drawn from a series of candidate scenarios [42], and each respondent was required to complete eight pairs of choice tasks.

Given the fact that there was no general standard on the ideal sample size required for a DCE [43], we followed a rule-of-thumb [44] for determining the sample size:

$$\frac{nta}{c}\ge 500$$

where n was the number of respondents, t was the choice pairs for each block, a was the number of alternatives, and c equaled the largest number of levels for any attributes. Therefore, the minimum sample size for each block was 94, which was equivalent to a total sample size of 564.

We adopted unlabeled DCE, which had been widely used to explore patients’ preferences for health technologies [34, 45,46,47]. Respondents of unlabeled DCEs were not subject to the psychological cues of the technology labels, thus reflecting the real decisions [48]. In addition, we applied the forced-choice sets since when no option had a definitive advantage, forced-choice under preference uncertainty led to the selection of options that were relatively easy to justify and associated with a lower chance of error and regret [49]. Examples of choice scenarios are shown in Appendix 4.

Our questionnaire consisted of three parts. The first part included patients’ socioeconomic characteristics, medical history, and complications. The second part contained the DCE tasks. The final part presented patients’ comprehension and confidence when making DCE choices. The patients were asked to rate their own comprehension and confidence on a scale ranging from zero (worst case) to 10 (best case) (Appendix 5).

DCE implementation and data collection

The formal DCE was conducted from 9th November 2020 to 6th January 2021. Inclusion criteria were patients aged 18 years or older, participating in a health insurance program, diagnosed with type 2 diabetes for at least one year, and taking medications regularly. Patients were excluded if they had been diagnosed with gestational diabetes. There were nine sampling hospitals in four cities (i.e., Suzhou, Nantong, Yancheng, and Lianyungang) in Jiangsu Province. To ensure the representativeness of patients, the sampling hospitals consisted of tertiary, secondary, and primary hospitals. Patients were enrolled consecutively within each hospital.

To ensure the reliability and validity of the survey, our DCE questionnaires were administered via one-to-one, face-to-face interviews. Our interviewers comprised 10 medical interns and 27 physicians. For quality assurance, we compiled a survey manual and trained the interviewers before the experiment. Interviewers were trained on a one-to-one basis, either face-to-face or online, to make them fully comprehend the requirements of the survey. To assure completeness of the questionnaire, the interviewers were required to check each questionnaire immediately after the survey was completed. For patients who were illiterate or had blurred vision, the interviewers explained each item of the questionnaire in detail until the patients fully understood. Medical history and clinical information like complications in the questionnaire were checked from electronic medical records.

We supposed that due to the constrained budget of public health insurance, only one drug could be reimbursed. Patients were asked to think carefully and make trade-offs between the new drugs. Each survey took 20 min to one hour. Patients’ participation in the survey was anonymous and voluntary, and their informed and verbal consent was obtained prior to the survey.

Statistical analysis

Our DCE data analysis was based on the random utility maximization theory [50, 51]. The utility (U) that patient, i, assigned to choice, j, consists of two parts [42]. One is the observable component Vij, which is determined by patients’ preferences for attributes. The other is the random component εij, representing the random error term with standard statistical properties. Therefore, the utility that a patient gets from choices can be expressed in the following equations:

$${U}_{ij}={V}_{ij}+{\epsilon }_{ij}={\beta }_{0}+{\beta }_{1}{X}_{1ij}+{\beta }_{2}{X}_{2ij}+\dots +{\beta }_{m}{X}_{mij}+{\epsilon }_{ij}$$

where β quantifies the strength of preference for each attribute level [42]. Each estimated coefficient is a preference weight and represents the relative contribution of the attribute level to the utility that respondents assigned to an alternative.

We implemented the above equation by mixed logit regression using STATA 14.2 SE (STATA Corp LLC, College Station, Texas, USA). Maximum simulated likelihood leads to the reasonable accuracy of estimation results [52, 53]. Therefore, we first specified the mixed logit model with 500, 1000, 1,500, and 2,000 Halton draws respectively. After that, we selected the specification with 1,500 Halton draws due to the maximum simulated likelihood estimation of the model. Based on effects coding, a positive coefficient indicated that patients would prefer this attribute level compared to the mean effect, while a negative coefficient showed that patients would prefer this level less than the mean effect [54]. The relative importance (RI) of each attribute was calculated based on the overall utility value of the attribute (i.e., the differences between the highest and lowest coefficients of each attribute) divided by the sum of overall utility values across all attributes [55, 56].

To go further into the assessment of preference heterogeneity, we established models that included interaction terms between individual-specific characteristics and attributes, as suggested by Umar et al. [57]. The identified interaction terms were drug attributes with age, level of income, and diabetes complications. The mixed logit regression model that involved interaction terms was as follows:

$$\eqalign{{U}_{ij} & = {\beta }_{0}+{\beta }_{1}{X}_{1ij}+{\beta }_{2}{X}_{2ij}+\dots \cr & +{\beta }_{m}{X}_{mij}+{\beta }_{s1}{X}_{1ij}{S}_{interaction\_term}\cr & +{\beta }_{s2}{X}_{2ij}{S}_{interaction\_term}+\dots \cr & +{\beta }_{sm}{X}_{mij}{S}_{interaction\_term}{+ \epsilon }_{ij}}$$

where β1−βm quantified the strength of preference for each attribute, βs1−βsm represented the parameter weights for interaction terms, and XmijSinteraction_term was the interaction terms. The Chi-square test for joint significance was performed to evaluate whether preferences varied. The statistically significant interaction effects would indicate that patients’ preferences differed by specific characteristics [58]. The positive coefficients of interaction terms suggest that compared with a subgroup of patients without a certain characteristic, the subgroup of patients with the characteristic attached more importance to an attribute [59]. While the negative coefficients of interaction terms suggest that the subgroup of patients with a certain characteristic attached less importance to an attribute than the comparators [59].


Patients’ characteristics

A total of 670 patients consented to participate in our DCE survey. Of them, 31 were excluded from the analysis due to incomplete data, a lack of understanding, or no confidence in making DCE choices. As a result, data from 639 patients were available for analysis. The average age of the patients was 65.59 years old. 344 patients (53.83%) had monthly household income equal to or less than CNY 6000. 306 patients (47.89%) had diabetes complications. On average, the study patients found it easy to understand the scenarios (8.31, 95% CI 8.25–8.36), and confident in their choices (9.17, 95% CI 9.10–9.24). Further demographic characteristics of the patients are presented in Table 2.

Table 2 Demographic characteristics of the study patients (N = 639)

Main model estimation of preferences

As shown in Table 3, HbA1c control, the incidence of serious side effects, length of extended life, change in HRQoL, dosing frequency, and out-of-pocket costs significantly influenced patients’ new drug choices for insurance coverage. The relative importance, based on the ranking of attribute coefficients for highest versus lowest levels, showed that change in HRQoL was the most important consideration, followed by the length of extended life, HbA1c control, out-of-pocket costs, the incidence of serious side effects, and dosing frequency. The most important attribute level was significant improvement in HRQoL (β = 1.383, p < 0.001), followed by longer extended life (β = 0.787, p < 0.001), and well-controlled HbA1c (β = 0.724, p < 0.001). On the other hand, the out-of-pocket cost was a negative predictor of their preferences (β = -0.138, p < 0.001).

Table 3 Estimation of preferences from the mixed logit model

Interaction-effects model estimation of preference heterogeneity

The model estimation of the interaction effects with each attribute is listed in Table 4. Compared with patients who were less than 65 years old, elderly patients showed stronger preferences for drugs with a lower incidence of serious side effects (β = 0.358, p < 0.01) and less out-of-pocket costs (β= -0.107, p < 0.01) (Model 1). While young or mid-aged patients would be more likely to choose drugs with the lowest incidence of serious side effects (β= -0.333, p < 0.01).

Table 4 Estimation of preference heterogeneity from interaction-effects models

Similarly, we tested for interactions of income with the attributes. During the decision-making process, low-income patients conferred much more importance on out-of-pocket costs (β= -0.175, p < 0.001) and the well-control of HbA1c (β = 0.542, p < 0.001) than the high-income patients (Model 2).

The interaction terms regarding diabetes complications with three attributes were statistically significant (Model 3). Compared with patients without complications, patients who had complications favored more in the length of extended life (β = 0.404, p < 0.01), improvement in HRQoL (β = 0.402, p < 0.05), and less out-of-pocket costs (β= -0.156, p < 0.001).


Diabetes is a complex and multi-causal disorder that is associated with considerable morbidity and mortality among patients and results in a heavy burden on healthcare resources. The global costs of diabetes are huge and will substantially increase, which calls for policymakers to take urgent actions to prepare health and social security systems to ensure affordable access to anti-diabetic drugs [60]. What’s more, thousands of new anti-diabetes drugs are synthesized each year. The reimbursement of new drugs that meet patient needs is of global interest. Meanwhile, the fulfillment of patients’ expectations of insurance benefits is the major predictor of satisfaction with health insurance [15]. Our study contributes to the understanding and incorporation of patient preferences into health insurance decision-making, thus informing policymakers to make coverage and reimbursement strategies more effective and resulting in higher patient satisfaction.

We found that patients’ preferred new anti-diabetic drugs for public health insurance coverage comprising the following attributes: improving patient-reported health status as reflected by HRQoL, bringing long-term health benefits, producing the expected treatment effects, causing few serious side effects, and having convenient dosing frequency. Patients’ preferences for multiple attribute values of new anti-diabetic drugs highlight the importance of systematic assessment and deliberate trade-offs of drugs during the decision-making process.

Among the attributes, health benefits defined as optimal HRQoL, extended life expectancy, and satisfied HbA1c control were the most influential drivers of insurance coverage preferences. A systematic review showed that HRQoL was an essential attribute in the value-assessment framework for new medicines [61]. Length of extended life years represented the long-term benefits of the new drugs, while HbA1c control was the primary outcome measure in evidence-based clinical practice guidelines. Improvements in health outcomes were also identified as the main factors that determined patients’ choices for anti-diabetic medicines in clinical practice [34, 62]. Accordingly, the effective interventions that can improve health outcomes can be included in the drug formulary and prioritized for reimbursement.

Our estimates of the main model also indicated that two attribute levels, the lowest incidence of serious side effects and the most convenient dosing, were statistically significant. However, dosing frequency was the least important attribute. Patients on average might be unwilling to trade quality of life and clinical benefits for convenience and safety. But our results were different from several previous studies. For example, a study found that diabetes patients in Germany and Spain were willing to trade efficacy for improvements in side effects [32]. Another study found that key determinants of treatment preferences among diabetes patients in Germany and the United Kingdom were side effects, efficacy, and dosing frequency [63]. It should be noted that only the HbA1c level was used as an attribute of health benefits in those studies. In our study, not only the clinical outcomes like HbA1c control but also attributes to reflect patient-reported outcomes (i.e., improvement in HRQoL) and long-term endpoints (i.e., extended life years) were involved. Meanwhile, we did not aim to assess patients’ preferences for therapeutic treatment; instead, we focused on the health insurance decisions.

To help policymakers better design health insurance schemes that satisfy individual patients’ needs, we explored preference heterogeneity. We had several new findings on the determinants of patients’ choices according to their demographic features. First, low-income patients were more concerned with the HbA1c control, as well as less out-of-pocket costs. This is consistent with prior study findings that a disproportionately low rate of receiving anti-diabetic medication and having blood glucose monitoring was observed among the low-income patients in China [64, 65]. China’s universal health insurance coverage has been based on a strategy of wide coverage with a relatively low level of benefit, causing concerns about the limited financial protection offered by insurance programs, especially for the low-income populations [7]. Effective new drugs covered by public health insurance should be accessible to low-income patients at the most affordable costs.

Second, older patients particularly favored new drugs with a low incidence of serious adverse events and less out-of-pocket costs. Age has been identified as a risk factor for serious adverse events like severe hypoglycemia [66, 67]. We also found that younger adults cared more about the never or rarely incidence of serious adverse events, probably due to the relatively lower rate of adverse events among them. Our results inform insurance decision-makers to establish monitoring mechanisms for drug-related serious adverse events among older adults. The likelihood of morbidity and mortality increases with the aging process, which leads to a higher probability of out-of-pocket cost burden among older adults with diabetes [68]. The higher out-of-pocket costs, coupled with lower average incomes for older adults, might account for a higher economic burden than the younger adults [69]. Therefore, compared to the general population, it is necessary to further expand the reimbursement ratio of public health insurance for older adults, especially those with low incomes.

Finally, patients with diabetes complications expressed stronger preferences for the new drugs that contributed to the improvement of HRQoL, extended life years, and had less out-of-pocket costs. It has been proved that patients with complications have considerable impairment in HRQoL and suffered from life-year loss [70, 71]. Despite China’s efforts in improving its healthcare system, the financial burden for diabetes patients suffering from complications was still substantial, and some families became impoverished due to medical expenditures associated with the complications [72]. Likewise, the growing pressures on cost containment of rising healthcare expenditure require scrutiny and assessment of drugs for better value for patients with complications.

The major contributions of our DCE are as follows. First, we used a DCE which followed good research practices, offering the advantage to measure trade-offs in patient choices, quantify the strength of preferences and identify preference heterogeneity. Second, we involved attributes from clinical benefits, long-term endpoints, patient-reported outcomes, safety, convenience, and out-of-pocket costs. Our findings would be helpful for policymakers’ better understanding of the multi-attribute value of new anti-diabetic drugs. Third, we captured preference heterogeneity evidence to help policymakers make health insurance decisions more patient-centered.

Despite the strengths, several limitations of our study should be acknowledged. First, our samples were from Jiangsu province, which represents one of the most economically developed regions in China. Future studies should draw a nationally representative sample by including the economically underdeveloped regions. Second, we only selected a subset of prominent attributes that were identified from the literature review and focus group discussion. Our analysis did not address other attributes that might be meaningful to patients. Third, the role of private health insurance in extending universal health insurance coverage in China is limited at present. We are not sure whether the results are applicable to private health insurance schemes. Fourth, our study provides evidence of patients’ preferences for the multi-attribute value of new anti-diabetic drugs. Future studies are suggested to enroll patients with other types of diseases. Meanwhile, given the complexity of the health insurance system, we also recommend researchers to conduct studies to assess patients’ preferences for insurance plans, copayments, etc. Finally, DCEs pose hypothetical choices, which may not fully represent the choices respondents have or would make in real-world decision scenarios.


In summary, our study showed that diabetes patients, in general, valued several attributes of new drugs, including effectiveness, patient-reported outcomes, economic consequences, safety, and convenience. The most influential drivers of patient preferences were health benefits like satisfied HRQoL, extended life years, and well-controlled HbA1c. Our findings also underline the value of accounting for preference heterogeneity in policy-making. Patient-centered public health insurance decision-making should be promoted, so as to enable the improved health outcomes and satisfaction of patients.

Data Availability

Original datasets will be available upon reasonable request to the corresponding author.



Health technology assessment.


Discrete choice experiment.

HbA1c :

Glycated haemoglobin A1c.


Health-related quality of life.


Relative importance.


  1. International Diabetes Federation. IDF Diabetes Atlas, 9th edition. Brussels, Belgium: International Diabetes Federation; 2019.

  2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.

  3. Adibe MO, Anosike C, Nduka SO, Isah A. Evaluation of health status of type 2 diabetes outpatients receiving care in a tertiary hospital in Nigeria. Pharm Econ. 2018;2(3):337–45.

    Article  Google Scholar 

  4. Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020;162:108072.

  5. Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, et al. SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. Diabetes Ther. 2020;11(12):2757–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Luo Z, Fabre G, Rodwin VG. Meeting the challenge of diabetes in China. Int J Health Policy. 2020;9(2):47–52.

    Article  Google Scholar 

  7. Yu H. Universal health insurance coverage for 1.3 billion people: what accounts for China’s success. Health Policy. 2015;119(9):1145–52.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Yip W, Fu H, Chen AT, Zhai T, Jian W, Xu R, et al. 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet. 2019;394(10204):1192–204.

    Article  PubMed  Google Scholar 

  9. Wang J, Zhu H, Liu H, Wu K, Zhang X, Zhao M, et al. Can the reform of integrating health insurance reduce inequity in catastrophic health expenditure? Evidence from China. Int J Equity Health. 2020;19(1):49.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Central Committee of the Communist Party of China and the State Council. Opinions of the Central Committee of the Communist Party of China and the State Council on Deepening the Reform of the Medical Security System. 2020. Accessed 20 Jul 2022.

  11. China’s National Healthcare Security Administration. Interim Measures for the Administration of Basic Medical Insurance. 2020. Accessed 20 Jul 2022.

  12. Center for Drug Evaluation of the National Medical Products Administration in China. Benefit-Risk Assessment Technical Guidelines for Patient-Centered Clinical Trials (Draft Version). 2022. Accessed 20 Aug 2022.

  13. van Overbeeke E, Forrester V, Simoens S, Huys I. Use of patient preferences in health technology assessment: perspectives of Canadian, Belgian and German HTA representatives. Patient. 2021;14(1):119–28.

    Article  PubMed  Google Scholar 

  14. Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care. 2007;23(1):30–5.

    Article  PubMed  Google Scholar 

  15. Geng J, Chen X, Shi J, Bao H, Chen Q, Yu H. Assessment of the satisfaction with public health insurance programs by patients with chronic diseases in China: a structural equation modeling approach. BMC public health. 2021;21(1):1886.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Liu X, Yang F, Cheng W, Wu Y, Cheng J, Sun W, et al. Mixed methods research on satisfaction with basic medical insurance for urban and rural residents in China. BMC Public Health. 2020;20(1):1201.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Dirksen CD. The use of research evidence on patient preferences in health care decision-making: issues, controversies and moving forward. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):785–94.

    Article  PubMed  Google Scholar 

  18. Marsh K, Caro JJ, Zaiser E, Heywood J, Hamed A. Patient-centered decision making: lessons from multi-criteria decision analysis for quantifying patient preferences. Int J Technol Assess Health Care. 2018;34(1):105–10.

    Article  PubMed  Google Scholar 

  19. Chachoua L, Dabbous M, François C, Dussart C, Aballéa S, Toumi M. Use of patient preference information in benefit-risk assessment, health technology assessment, and pricing and reimbursement decisions: a systematic literature review of attempts and initiatives. Front Med (Lausanne). 2020;7:543046.

    Article  Google Scholar 

  20. Aysola J, Xu C, Huo H, Werner RM. The relationships between patient experience and quality and utilization of primary care services. J Patient Exp. 2020;7(6):1678–84.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Pantaleon L. Why measuring outcomes is important in health care. J Vet Intern Med. 2019;33(2):356–62.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Bombard Y, Baker GR, Orlando E, Fancott C, Bhatia P, Casalino S, et al. Engaging patients to improve quality of care: a systematic review. Implement Sci. 2018;13(1):98.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wei Y, Ming J, Shi L, Ke X, Sun H, Chen Y. Physician-patient shared decision making, patient satisfaction, and adoption of new health technology in China. Int J Technol Assess Health Care. 2020;36(5):518–24.

    Article  PubMed  Google Scholar 

  24. Leopold C, Lu CY, Wagner AK. Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand. BMC Health Serv Res. 2020;20(1):351.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of patient preference studies in HTA decision making: a NICE perspective. Patient. 2020;13(2):145–9.

    Article  PubMed  Google Scholar 

  26. Lee HY, Bae EY, Lee K, Kang M, Oh J. Public preferences in resource allocation for insurance coverage of dental implant service in South Korea: citizens’ jury. Int J Environ Res Public Health. 2021;18(8):4135.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Pharmaceutical Benefits Advisory Committee (PBAC). EXENATIDE 2 mg, powder for injection, vial Bydureon®AstraZeneca Pty Ltd. In: Draft Public Summary Document – July 2015 PBAC Meeting. Accessed 20 Aug 2022.

  28. Kjaer T, Gyrd-Hansen D. Preference heterogeneity and choice of cardiac rehabilitation program: results from a discrete choice experiment. Health Policy. 2008;85(1):124–32.

    Article  PubMed  Google Scholar 

  29. Quaife M, Terris-Prestholt F, Di Tanna GL, Vickerman P. How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity. Eur J Health Econ. 2018;19(8):1053–66.

    Article  PubMed  Google Scholar 

  30. de Bekker-Grob EW, Swait JD, Kassahun HT, Bliemer MCJ, Jonker MF, Veldwijk J, et al. Are healthcare choices predictable? The impact of discrete choice experiment designs and models. Value Health. 2019;22(9):1050–62.

    Article  PubMed  Google Scholar 

  31. Mühlbacher AC, Sadler A, Juhnke C. Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment. Eur J Health Econ. 2021;22(3):425–43.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, et al. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017;8(6):1365–78.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Igarashi A, Bekker Hansen B, Langer J, Tavella F, Collings H, Davies N, et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment. Adv Ther. 2021;38(1):721–38.

    Article  CAS  PubMed  Google Scholar 

  34. Donnan JR, Johnston K, Chibrikov E, Marra CA, Aubrey-Bassler K, Najafzadeh M, et al. Capturing adult patient preferences toward benefits and risks of second-line antihyperglycemic medications used in type 2 diabetes: a discrete choice experiment. Can J Diabetes. 2020;44(1):6–13.

    Article  PubMed  Google Scholar 

  35. Pham TB, Nguyen TT, Truong HT, Trinh CH, Du HNT, Ngo TT, et al. Effects of diabetic complications on health-related quality of life impairment in Vietnamese patients with type 2 diabetes. J Diabetes Res. 2020;2020:4360804.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Jiao F, Wong CKH, Gangwani R, Tan KCB, Tang SCW, Lam CLK. Health-related quality of life and health preference of Chinese patients with diabetes mellitus managed in primary care and secondary care setting: decrements associated with individual complication and number of complications. Health Qual Life Outcomes. 2017;15(1):125.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes care. 2012;35(12):2650–64.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Jing Z, Chu J, Imam Syeda Z, Zhang X, Xu Q, Sun L, et al. Catastrophic health expenditure among type 2 diabetes mellitus patients: A province-wide study in Shandong, China. J Diabetes Investig. 2019;10(2):283–9.

    Article  PubMed  Google Scholar 

  39. Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Rindress D. Evidence and value: impact on decisionmaking–the EVIDEM framework and potential applications. BMC Health Serv Res. 2008;8:270.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Geng J, Chen X, Yu X, Huang J, He D, Dong J. Study on the evidence-based decision making framework for reimbursement technologies in view of EVIDEM. Chin J Health Policy. 2018;11(4):50–4.

    Article  Google Scholar 

  41. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13.

    Article  CAS  PubMed  Google Scholar 

  42. Ryan M, Kolstad J, Rockers P, Dolea C. How to conduct a discrete choice experiment for health workforce recruitment and retention in remote and rural areas: a user guide with case studies. Geneva: World Health Organization Press; 2012.

    Google Scholar 

  43. de Bekker-Grob EW, Donkers B, Jonker MF, Stolk E. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373–84.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Johnson R, Orme B. Sample size issues for conjoint analysis In: Getting started with conjoint analysis: strategies for product design and pricing research. edition. Edited by Orme B. Madison: Research Publishers; 2010;57–66.

  45. Bhattarai N, McMeekin P, Price CI, Vale L. Preferences for centralised emergency medical services: discrete choice experiment. BMJ Open. 2019;9(11):e030966.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Damm K, Lingner H, Schmidt K, Aumann-Suslin I, Buhr-Schinner H, van der Meyden J, et al. Preferences of patients with asthma or COPD for treatments in pulmonary rehabilitation. Health Econ Rev. 2021;11(1):14.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Alkhoury D, Atchison J, Trujillo AJ, Oslin K, Frey KP, O’Toole RV, et al. Can financial payments incentivize short-term smoking cessation in orthopaedic trauma patients? Evidence from a discrete choice experiment. Health Econ Rev. 2021;11(1):15.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kløjgaard ME, Bech M, Søgaard R. Designing a stated choice experiment: the value of a qualitative process. J Choice Model. 2012;5(2):1–18.

    Article  Google Scholar 

  49. Dhar R, Simonson I. The effect of forced choice on choice. J Mark Res. 2003;40(2):146–60.

    Article  Google Scholar 

  50. Manski CF. The structure of random utility models. Theory Decis. 1977;8(3):229–54.

    Article  Google Scholar 

  51. Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharm Econ. 2008;26(8):661–77.

    Article  Google Scholar 

  52. Haan P, Uhlendorf A. Estimation of multinomial logit models with unobserved heterogeneity using maximum simulated likelihood. STATA J. 2006;6(2):229–45.

    Article  Google Scholar 

  53. Hole AR. Fitting mixed logit models by using maximum simulated likelihood. STATA J. 2007;7(3):388–401.

    Article  Google Scholar 

  54. Mühlbacher AC, Sadler A, Dippel FW, Juhnke C. Treatment preferences in germany differ among apheresis patients with severe hypercholesterolemia. Pharm Econ. 2018;36(4):477–93.

    Article  Google Scholar 

  55. Hertroijs LDF, Elissen AMJ, Brouwers MCGJ, Hiligsmann M, Schaper NC, Ruwaard D. Preferences of people with type 2 diabetes for diabetes care: a discrete choice experiment. Diabet Med. 2020;37(11):1807–15.

    Article  CAS  PubMed  Google Scholar 

  56. Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. Cambridge: Cambridge University Press; 2000.

    Book  Google Scholar 

  57. Umar N, Quaife M, Exley J, Shuaibu A, Hill Z, Marchant T. Toward improving respectful maternity care: a discrete choice experiment with rural women in northeast Nigeria. BMJ Glob Health. 2020;5(3):e002135.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Fu P, Wang Y, Liu S, Li J, Gao Q, Zhou C, et al. Analysing the preferences for family doctor contract services in rural China: a study using a discrete choice experiment. BMC Fam Pract. 2020;21(1):148.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Kruk ME, Johnson JC, Gyakobo M, Agyei-Baffour P, Asabir K, Kotha SR, et al. Rural practice preferences among medical students in Ghana: a discrete choice experiment. Bull World Health Organ. 2010;88(5):333–41.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, et al. Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030. Diabetes Care. 2018;41(5):963–70.

    Article  PubMed  Google Scholar 

  61. Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2018;19(1):123–52.

    Article  PubMed  Google Scholar 

  62. Mühlbacher A, Bethge S. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Eur J Health Econ. 2016;17(9):1125–40.

    Article  PubMed  Google Scholar 

  63. Qin L, Chen S, Flood E, Shaunik A, Romero B, de la Cruz M, et al. Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-experienced patients with type 2 diabetes mellitus: a preference study in Germany and the United Kingdom. Diabetes Ther. 2017;8(2):335–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Wang Z, Li X, Chen M. Socioeconomic factors and inequality in the prevalence and treatment of diabetes among middle-aged and elderly adults in China. J Diabetes Res. 2018;2018:1471808.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Lai S, Shen C, Yang X, Zhang X, Xu Y, Li Q, et al. Socioeconomic inequalities in the prevalence of chronic diseases and preventive care among adults aged 45 and older in Shaanxi province, China. BMC Public Health. 2019;19(1):1460.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Hermann M, Heimro LS, Haugstvedt A, Hernar I, Sigurdardottir AK, Graue M. Hypoglycaemia in older home-dwelling people with diabetes- a scoping review. BMC Geriatr. 2021;21(1):20.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Ikeda Y, Kubo T, Oda E, Abe M, Tokita S. Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis. J Diabetes Investig. 2018;9(4):925–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Zhang P, Imai K. The relationship between age and healthcare expenditure among persons with diabetes mellitus. Expert Opin Pharmacother. 2007;8(1):49–57.

    Article  PubMed  Google Scholar 

  69. Jiang Q, Yang S, Sánchez-Barricarte JJ. Can China afford rapid aging? SpringerPlus. 2016;5(1):1107–7.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Gu S, Wang X, Shi L, Sun Q, Hu X, Gu Y, et al. Health-related quality of life of type 2 diabetes patients hospitalized for a diabetes-related complication. Qual Life Res. 2020;29(10):2695–704.

    Article  PubMed  Google Scholar 

  71. Heald AH, Stedman M, Davies M, Livingston M, Alshames R, Lunt M, et al. Estimating life years lost to diabetes: outcomes from analysis of National Diabetes Audit and Office of National Statistics data. Cardiovasc Endocrinol Metab. 2020;9(4):183–5.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Liu X, Chu H, Zhao J, Qiao R, Liu Y, Li N, et al. Exploring the barriers of patients with diabetic foot complications in China: a qualitative interview study. Ann Transl Med. 2021;9(9):792–2.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


We acknowledge the contributions made by our interviewers who did one-to-one, face-to-face interviews with the patients. We are grateful to the patients for their efforts and time. When drafting the research protocol, Jinsong Geng was a research fellow at the Fellowship in Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute. We sincerely thank reviewers for their insightful and constructive comments.


This work was supported by MOE (Ministry of Education in China) Project of Humanities and Social Sciences (Grant No. 21YJAZH023), Science and Technology Project of Nantong City (Grant No. MS12021064), and National Natural Science Foundation of China (Grant No. 71603138). The funders provided financial support for the conduct of the study. The funders had no role in the design, implementation, data collection and statistical analysis, data interpretation, or writing of the manuscript.

Author information

Authors and Affiliations



Geng JS and Yu H led the design and analysis of the discrete choice experiment. Bao HN and Yu XL contributed to the literature search and qualitative analysis. Geng JS and Meng JY took part in the design of the questionnaire and interpretation of the data. Geng JS, Bao HN, and Feng Z contributed to implementing the discrete choice experiment. Geng JS and Bao HN performed the statistical analysis and wrote the manuscript. Yu H provided comments on the manuscript.

Corresponding author

Correspondence to Jinsong Geng.

Ethics declarations

Ethics approval and consent to participate

This study, including the patient consent process, has been approved by the Medical Ethics Committee at Nantong University (Ethical Approval-2021070) and conforms to the ethical guidelines of the Declaration of Helsinki. Informed, verbal consent was obtained from all individual participants in the study. The verbal informed consent has also been approved by the Medical Ethics Committee at Nantong University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jinsong Geng and Haini Bao contributed equally to the research and should be considered co-first authors.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Geng, J., Bao, H., Feng, Z. et al. Investigating patients’ preferences for new anti-diabetic drugs to inform public health insurance coverage decisions: a discrete choice experiment in China. BMC Public Health 22, 1860 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: